Verona Pharma Plc ADR (VRNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2025 | 03-2025 | 12-2024 | 09-2024 | 06-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,398 | -16,319 | -173,418 | -139,591 | -96,629 |
| Depreciation Amortization | 1,934 | 949 | 2,362 | 1,576 | 818 |
| Accounts receivable | -51,362 | -30,663 | -31,496 | -6,904 | N/A |
| Other Working Capital | -51,321 | -35,259 | -5,737 | 9,139 | 41,280 |
| Other Operating Activity | 124,147 | 69,731 | 86,086 | 42,413 | 23,819 |
| Operating Cash Flow | $19,000 | $-11,561 | $-122,203 | $-93,367 | $-30,712 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -535 | -535 | -580 | -45 | -45 |
| Investing Cash Flow | $-535 | $-535 | $-580 | $-45 | $-45 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | -109,921 | 100,000 | 100,000 | 100,000 |
| Debt Issued | 122,500 | 122,500 | 122,500 | 122,500 | 122,500 |
| Common Stock Issued | 10,108 | 5,165 | 102,904 | 4,484 | 816 |
| Other Financing Activity | -114,208 | -4,287 | -74,625 | -70,362 | -59,607 |
| Financing Cash Flow | $18,400 | $13,457 | $250,779 | $156,622 | $163,709 |
| Exchange Rate Effect | 1,394 | 297 | -11 | 1,058 | -125 |
| Beginning Cash Position | 399,757 | 399,757 | 271,772 | 271,772 | 271,772 |
| End Cash Position | 438,016 | 401,415 | 399,757 | 336,040 | 404,599 |
| Net Cash Flow | $38,259 | $1,658 | $127,985 | $64,268 | $132,827 |
| Free Cash Flow | |||||
| Operating Cash Flow | 19,000 | -11,561 | -122,203 | -93,367 | -30,712 |
| Capital Expenditure | -535 | -535 | -580 | -45 | -45 |
| Free Cash Flow | 18,465 | -12,096 | -122,783 | -93,412 | -30,757 |